1. Economic evaluation alongside a clinical trial of near-to-patient testing for sexually transmitted infections.
- Author
-
Zhang Y, Vodstrcil LA, Htaik K, Plummer EL, De Petra V, Sen MG, Williamson DA, Owlad M, Murray G, Chow EP, Fairley CK, Bradshaw CS, and Ong JJ
- Subjects
- Humans, Male, Female, Gonorrhea diagnosis, Gonorrhea economics, Gonorrhea drug therapy, Australia, Adult, Cost-Benefit Analysis, Chlamydia Infections diagnosis, Chlamydia Infections economics, Chlamydia Infections drug therapy, Chlamydia trachomatis, Neisseria gonorrhoeae isolation & purification, Mycoplasma genitalium, Mass Screening economics, Mass Screening methods, Mycoplasma Infections diagnosis, Mycoplasma Infections drug therapy, Mycoplasma Infections economics, Urethritis diagnosis, Urethritis economics, Urethritis drug therapy, Urethritis microbiology, Sexually Transmitted Diseases diagnosis, Sexually Transmitted Diseases economics, Sexually Transmitted Diseases drug therapy
- Abstract
Background: Current clinical care for common bacterial STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG)) involves empiric antimicrobial therapy when clients are symptomatic, or if asymptomatic, waiting for laboratory testing and recall if indicated. Near-to-patient testing (NPT) can improve pathogen-specific prescribing and reduce unnecessary or inappropriate antibiotic use in treating sexually transmitted infections (STI) by providing same-day delivery of results and treatment., Methods: We compared the economic cost of NPT to current clinic practice for managing clients with suspected proctitis, non-gonococcal urethritis (NGU), or as an STI contact, from a health provider's perspective. With a microsimulation of 1000 clients, we calculated the cost per client tested and per STI- and pathogen- detected for each testing strategy. Sensitivity analyses were conducted to assess the robustness of the main outcomes. Costs are reported as Australian dollars (2023)., Results: In the standard care arm, cost per client tested for proctitis, NGU in men who have sex with men (MSM) and heterosexual men were the highest at $247.96 (95% Prediction Interval (PI): 246.77-249.15), $204.23 (95% PI: 202.70-205.75) and $195.01 (95% PI: 193.81-196.21) respectively. Comparatively, in the NPT arm, it costs $162.36 (95% PI: 161.43-163.28), $158.39 (95% PI: 157.62-159.15) and $149.17 (95% PI: 148.62-149.73), respectively. Using NPT resulted in cost savings of 34.52%, 22.45% and 23.51%, respectively. Among all the testing strategies, substantial difference in cost per client tested between the standard care arm and the NPT arm was observed for contacts of CT or NG, varying from 27.37% to 35.28%., Conclusion: We found that NPT is cost-saving compared with standard clinical care for individuals with STI symptoms and sexual contacts of CT, NG, and MG., Competing Interests: Declaration of Competing Interest CSB and CKF were supported by an Australian National Health and Medical Research Council Leadership Investigator Grant (GNT1173361 and GNT1172900, respectively). JJO and EPFC are supported by an Australian National Health and Medical Research Council Emerging Leadership Investigator Grant (GNT1193955 and GNT1172873). YZ is supported by an Australian Government Research Training Program (RTP) scholarship. All other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF